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Abstract
Background: A genome-wide search for genes that predispose to type 1 diabetes using linkage
analysis was performed using 900 microsatellite markers in 70 nuclear families with affected siblings
from Finland, a population expected to be more genetically homogeneous than others, and having
the highest incidence of type 1 diabetes in the world and, yet, the highest proportion in Europe of
cases (10%) carrying neither of the highest risk HLA haplotypes that include DR3 or DR4 alleles.
Results: In addition to the evidence of linkage to the HLA region on 6p21 (nominal p = 4.0 × 10-
6), significant evidence of linkage in other chromosome regions was not detected with a single-locus
analysis. The two-locus analysis conditional on the HLA gave a maximum lod score (MLS) of 3.1
(nominal p = 2 × 10-4) on chromosome 9p13 under an additive model; MLS of 2.1 (nominal p = 6.1
× 10-3) on chromosome 17p12 and MLS of 2.5 (nominal p = 2.9 × 10-3) on chromosome 18p11
under a general model.
Conclusion: Our genome scan data confirmed the primary contribution of the HLA genes also in
the high-risk Finnish population, and suggest that non-HLA genes also contribute to the familial
clustering of type 1 diabetes in Finland.
Background
Type 1 diabetes is the third most prevalent chronic disease
of childhood, affecting 0.4% of the general population by
age of 30 years and has a lifetime risk of nearly 1% [1,2].
The incidence of type 1 diabetes varies very significantly
between populations [1,3-6]. A 30-fold difference in type
1 diabetes risk has been detected worldwide with the
highest incidence of the disease in Finland and the lowest
incidence of the disease in Asia [4-7]. The etiology of type
1 diabetes is unknown, but it is recognized to be due to
both genetic and environmental determinants [8,9].
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The observation of familial clustering of type 1 diabetes
suggests that genetic factors are involved in the etiology of
type 1 diabetes. For people of European ancestry, the fre-
quency of type 1 diabetes in siblings of affected individu-
als is about 6% by the age of 30 [10,11], while the
frequency in the general population is about 0.4–0.5% by
the age of 30 [2]. Thus, type 1 diabetes is about 15 times
(6/0.4) more common in siblings of type 1 diabetic
patients than in the general population. The risk of type 1
diabetes increased also in the offspring of diabetic
patients, to about 3–6% [12]. The concordance rate for
type 1 diabetes has been found to be higher in monozy-
gotic (MZ, 100% shared genes) than in dizygotic (DZ,
average 50% shared genes) twins, with cumulative MZ
rates approximately 35–50% [13-18]. The population-
based Finnish [18] and Danish [17] studies have revealed
that genetic factors may contribute approximately
75–80% of the liability to type 1 diabetes. The high dis-
cordance between MZ twins, however, suggests that the
penetrance of the type 1 susceptibility genes is low.
Following the lead from gene identification studies in rare
Mendelian diseases and the clear evidence of linkage of
the MHC in human and mouse to type 1 diabetes,
genome-wide scans for linkage to type 1 diabetes were
undertaken [19-26]. These studies all confirmed the
importance of HLA-encoded susceptibility to type 1 dia-
betes (designated also as IDDM1); and also excluded the
possibility of a locus with an effect equivalent to HLA. The
individual impact of other susceptibility genes is, there-
fore, much smaller than that of HLA. Nevertheless, statis-
tically significant and suggestive evidence of linkage of
type 1 diabetes to at least ten chromosome regions has
been published, although association studies at INS [27]
and CTLA4 have been required to confirm with fine map
loci. These newly identified susceptibility loci showed evi-
dence for linkage in some studies but could not be repli-
cated in others. The discrepancies between the studies
may be due to a number of factors, including sample size,
genetic and phenotypic heterogeneity between data sets,
genotyping methods, gender-specific effects and genetic
epistasis [12,28]. We are now reporting here the first
genome scan results using microsatellite markers among
Finnish nuclear families with at least two siblings affected
with type 1 diabetes. Finland is known to have a high
degree of population homogeneity genetically, compared
with most other countries because it has a distinct founder
population. Finnish type 1 diabetic patients have a high
frequency of non-DR3, non-DR4 positive HLA haplotypes
(approximately 10%), suggesting the possibility that non-
HLA loci, perhaps with a reasonable penetrance and pop-
ulation allelic frequency due to founder effects exists in
Finland.
Results
A total of 868 loci with a length of 3518 cM were actually
genotyped. Figures 1, 2, 3 show the MLS curves generated
using a single-locus analysis or a two-locus analysis fitted
under additive and general models for the action of the
two loci. The highest MLS was at chromosome 6p21, the
HLA region where the major type 1 diabetes susceptibility
gene(s) locates. For the two-locus analysis, we fixed mark-
ers with highest MLS at the HLA region to adjust for the
effect of HLA. Then the joint IBD sharing at the HLA locus
and at a second locus was considered, which was placed at
an increment of 1.0 cM across the genome. The MLS for
the effect of HLA was subtracted so that the curves in fig-
ures represent the additional contribution of locus 2. As
expected, at positions unlinked to HLA such as those on
different chromosomes, the multiplicative curves were
identical to those curves obtained by use of a single-locus
model for locus 2 and therefore were not presented in the
figures.
For a single-locus analysis, a MLS of 4.67 (nominal p = 4.0
× 10-6) at chromosome 6p21 (HLA region) was observed.
Another region, on 9p13 shows a MLS of 3.09 under
either a two-locus additive model (nominal p = 2 × 10-4)
or general model (nominal p = 4 × 10-4). Two other
regions on 17p12 and 18p11 showed positive findings
under two-locus general model (Table 1), with MLS of 2.1
and 2.5, respectively (which remains suggestive even after
the Bonferroni correction for the three tests performed –
single/multiplicative, additive and general – is applied).
Joint IBD sharing probabilities for an affected sibling pair
to share 0, 1 or 2 alleles IBD at 6p21 and each additional
locus under a general model are shown in Table 2.
Discussion
Our study of Finnish affected sib-pairs with type 1 diabe-
tes provides further evidence showing that the genes in the
HLA region are of the primary importance in this high-risk
population. Nevertheless, our results also add to the evi-
dence that there are non-HLA  loci with suggestive evi-
dence of linkage to three chromosome regions: 9p13,
17p12 and 18p11.
Recently, new methods to carry out whole-genome associ-
ation study using a large number of single nucleotide pol-
ymorphisms (SNPs) have become available. 18p11 has
been reported to have robust association in the first
genome-wide association study in type 1 diabetes along
with several other loci showing a significant association
[29]. The evidence of linkage to the chromosome 18p11
in our study was, however, modest, which might provide
a support to the findings from the above cited study or be
a mere chance. In a large study of 1435 multiplex families
the genome-wide linkage analysis of type 1 diabetesBMC Genetics 2007, 8:84 http://www.biomedcentral.com/1471-2156/8/84
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Genome-wide linkage analysis of type 1 diabetes (Chromosomes 1–9) Figure 1
Genome-wide linkage analysis of type 1 diabetes (Chromosomes 1–9). MLS resulted from the two-locus linkage anal-
ysis using TWOLOCARP in all affected sib pairs. Genetic distance (in Kosambi centi-Morgans) is given along the X-axis.BMC Genetics 2007, 8:84 http://www.biomedcentral.com/1471-2156/8/84
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Genome-wide linkage analysis of type 1 diabetes (Chromosomes 10–18) Figure 2
Genome-wide linkage analysis of type 1 diabetes (Chromosomes 10–18). MLS resulted from the two-locus linkage 
analysis using TWOLOCARP in all affected sib pairs. Genetic distance (in Kosambi centi-Morgans) is given along the X-axis.BMC Genetics 2007, 8:84 http://www.biomedcentral.com/1471-2156/8/84
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found linkage in none of the three non-HLA loci as we did
[19-26]. Taking into account the small sample size of our
current study, we need to be cautious when interpreting
our findings.
Current genotyping data originally was used to map loci
for nephropathy selecting for statistical analysis only sib-
pairs discordant (DSPs) for diabetic nephropathy [30].
For DSPs, linked markers will be characterized by dimin-
ished, as opposed to excessive, allele sharing between sibs
[31]. Therefore, the lod score peak at 6p21 in affacted sib-
pairs with type 1 diabetes, for example, was not revealed
in the same region in the DSPs analysis when diabetic
nephropathy was considered as the phenotype of interest.
This suggests that the findings in the current study were
not biased by the presence of nephropathy. However, the
findings need to be further examined. The significance of
our study is that we reconfirm the major significance of
HLA  genes and suggest that a linkage to chromosome
18p11 region might exist in this population with the high-
est risk of type 1 diabetes in the world.
Genome-wide linkage analysis of type 1 diabetes (Chromosomes 19–22 and Chromosome X) Figure 3
Genome-wide linkage analysis of type 1 diabetes (Chromosomes 19–22 and Chromosome X). MLS resulted from 
the two-locus linkage analysis using TWOLOCARP in all affected sib pairs. Genetic distance (in Kosambi centi-Morgans) is 
given along the X-axis.BMC Genetics 2007, 8:84 http://www.biomedcentral.com/1471-2156/8/84
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Conclusion
Our genome scan data confirmed the primary contribu-
tion of the HLA genes also in the high-risk Finnish popu-
lation, and suggest that non-HLA genes also contribute to
the familial clustering of type 1 diabetes in Finland.
Methods
Patients and families
DNA from 70 Finnish nuclear families with at least two
siblings affected with type 1 diabetes, including six fami-
lies with three and one family with four affected children
was collected from Finland. MODY families were not
included. A total of 207 individuals (147 sibs and 60 par-
ents) were genotyped, providing with 81 sib-pairs affected
with type 1 diabetes for linkage analysis. The original
study design was to collect DSPs, siblings affected with
type 1 diabetes but discordant for diabetic nephropathy,
to map loci for diabetic nephropathy[30]. Therefore, all
collected sib-pairs were affected with type 1 diabetes and
in each family at least one sibling was affected with neph-
ropathy. All sib-pairs were patients with type 1 diabetes
receiving insulin treatment since the onset of the disease.
In all affected sib-pairs the first patient was diagnosed
before the age of 18 years. Since the patients were ascer-
tained through the national data bases and many of them
were diagnosed in the 1970s or the early 1980s, detailed
clinical or biochemical data at diagnosis were not availa-
ble. There is however little doubt that the diabetic patients
would have other type of diabetes than type 1. The mean
(SD) age at onset of type 1 diabetes in the 147 siblings was
14.5 (10.4) years, ranging from 1.2–53.4 years. Informed
consent was obtained from all patients and their parents
whose DNA samples were collected. The study was
approved by the Ethical Committees of the Finnish
Table 1: Regions with MLS over 1.0 in either single- or two-locus linkage analysis
Chromosome Closest marker Location (cM) MLS (nominal p value)
Single Two-Locus Conditional on 6p21
Additive General
1q23 D1S1653 160 0.77 (0.0467) 0.43 (0.1240) 1.19 (0.0470)
2q34-36 D2S163 214 1.03 (0.0240) 0.99 (0.0327) 1.21 (0.0443)
3p21 D3S1581 64 0.51 (0.0935) 1.25 (0.0173) 1.25 (0.0407)
4q21 D4S1534 97 0.64 (0.0658) 0.29 (0.1876) 1.10 (0.0564)
6p21 D6S1575 58 4.67 (0.000004) NA NA NA NA
6q13 D6S1557 82 1.52 (0.0071) 0.06 (0.4040) 0.06 (0.5990)
6q16 D6S1709 109 1.68 (0.0048) 0.97 (0.0260) 0.97 (0.0770)
7p15 D7S516 36 0.49 (0.0987) 1.45 (0.0112) 1.45 (0.0277)
9p13 D9S1817 59 1.56 (0.0064) 3.09 (0.0002) 3.09 (0.0004)
12q14 D12S83 76 0.77 (0.0467) 0.29 (0.1876) 1.40 (0.0294)
13q32 D13S1298 74 0.43 (0.1167) 0.02 (0.4667) 1.23 (0.0428)
14q24 D14S986 77 1.15 (0.0177) 0.65 (0.0724) 1.53 (0.0241)
15q22 D15S1036 54 1.35 (0.0108) 1.65 (0.0064) 1.65 (0.0186)
17p12 D17S799 32 2.12 (0.0017) 1.65 (0.0064) 2.14 (0.0061)
18p11 D18S1163 22 1.83 (0.0033) 1.05 (0.0282) 2.47 (0.0029)
18p11 D18S453 42 1.18 (0.0164) 0.71 (0.0617) 1.30 (0.0366)
18q12 D18S457 55 1.06 (0.0222) 0.66 (0.0706) 1.17 (0.0487)
MLS was estimated using TWOLOCARP [38], the p value for a single-locus MLS was calculated using "possible triangle restriction" [39], and for a 
two-locus MLS obtained by Simulation.
NA: not available
Table 2: Joint IBD sharing probabilities for an affected sibling pair to share 0, 1 or 2 alleles IBD at 6p21 and each additional locus under 
a general model.
IBD sharing at 9p13 IBD sharing at 17p12 IBD sharing at 18p11
IBD sharing at 
6p21
012012012
0 0.000028 0.000057 0.057006 0.016443 0.054536 0.038093 0.027815 0.055631 0.027815
1 0.075956 0.151911 0.189911 0.032886 0.180947 0.148061 0.068961 0.137921 0.152572
2 0.117038 0.234076 0.174016 0.063655 0.264517 0.200863 0.057259 0.222837 0.24919BMC Genetics 2007, 8:84 http://www.biomedcentral.com/1471-2156/8/84
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National Public Health Institute, Helsinki, Finland and
the Karolinska Institute, Stockholm, Sweden.
Genotyping
DNA was extracted from peripheral lymphocytes, accord-
ing to standard procedures. A genome wide scan was per-
formed using 900 microsatellite markers and using
protocols described by Gretarsdottir et al.[32] at the geno-
typing laboratory of deCODE Genetics, Reykjavik, Ice-
land. Information of the microsatellite markers and
marker positions were obtained from the Marshfield
genetic map (Center for Medical Genetics, Marshfield
Medical Research Foundation). In the marker set used in
this study, the average spacing between markers was ~4
cM, with no gap > 10 cM. Standard PCR techniques with
fluorescently labeled primers were used to amplify poly-
morphic DNA fragments. The PCR products were supple-
mented with the internal size standard, separated and
detected on an Applied Biosystems model 377 Sequencer
by use of Genescan version 3.0 peak-calling software. Alle-
les were called automatically with TrueAllele program
(Cybergenetics) and the deCodeGT program was used to
fractionate according to quality and to edit the called gen-
otypes [33].
Linkage analysis
A generalization of maximum lod score (MLS) method
proposed by Risch [34] was used to assess the linkage in
all affected sib-pairs of each pedigree, which is based on
the measurement of the number of alleles (0,1,2) shared
identical by descent (IBD) by two affected sibs at a locus.
Genehunter (Version 2.0) was first used to estimate a sin-
gle-locus MLS. We report the nominal p-values for the
genome-wide single-locus analysis and note that in order
to control family-wise error rate (FWER) one could apply
Lander-Kruglyak critical value to obtain adjusted p-value.
Nominal p-values in the range of 10-4 were considered a
statistically significant threshold for linkage [35]. Thresh-
old MLS-LOD score values at 1.9 and 3.3 were considered
for "suggestive" and "significant" linkage, respectively
[36].
Two-locus analysis with Risch's method developed via an
extension of the method by Cordell [37,38] was then used
to estimate the MLS at either a single locus or a second
locus conditional on the HLA region, where the single-
locus MLS was greatest. The null hypothesis for a two-
locus analysis is that the locus 2 is not involved in disease,
and the results are given for a variety of two-locus models,
each fitted with the second locus placed at increments of
1.0 cM across the genome. The multiplicative model esti-
mates the conditional MLS at locus 2, taking account of
any effect at locus 1. If loci 1 and 2 are unlinked, the mul-
tiplicative conditional MLS for locus 2 will be identical to
the single locus MLS for locus 2. The additive and general
models calculate the conditional MLS at locus 2 taking
account of any effect at locus 1, assuming an additive
model for the joint action of loci 1 and 2, or allowing for
arbitrary epistasis between loci 1 and 2 in the general
model. Significance levels (nominal p values) for a single-
locus MLS were calculated according to the possible trian-
gle constraints described by Holmans [39] and for two-
locus MLS generated for this particular data set analyzed
using simulation [38].
To calculate the two-locus MLS, a prior as well as a poste-
rior probability that each affected sib-pair shares i alleles
IBD (i = 0,1,2) at particular positions on the genome is
required. For unlinked loci, the IBD probabilities were
obtained from the output of Genehunter (version 2.0)
[40,41] and for the linked loci on chromosome 6 they
were generated allowing for separate male and female
recombination fractions using MERLIN [42]. A single-
locus MLS for X chromosome was estimated using MAP-
MAKER/SIBS (version 2.0).
We also estimated the power of our sample to test for link-
age using the mean IBD sharing test [43] by computer
simulations. Depending on the degree of marker inform-
ativity assumed, we estimate that we have 56–72% power
to detect at p value 0.01 a locus accounting for a sibling
relative risk of 1.8, but only 33–41% to detect a locus
accounting for a sibling relative risk of 1.5. The power to
detect a locus-specific sibling relative risk of 1.8 at p value
0.001 is also less than 40%. This study clearly has limited
power to detect loci of small effect, but it is encouraging
that we have found suggestive evidence of linkage at three
loci in addition to the significant linkage on 6p21.
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